Choline

• Prenatal third-trimester supplementation for fetal brain development
• Correcting deficiency in vegans, vegetarians, and low-egg diets
• Preventing and reversing liver steatosis in long-term parenteral nutrition
• Cognition and focus protocols using citicoline or alpha-GPC forms
• General dietary adequacy where egg and organ-meat intake is low

Choline is an essential nutrient with extraordinary metabolic versatility, formally classified as essential by the Institute of Medicine in 1998 (the most recent essential nutrient designation), yet substantially under-recognized in consumer nutrition awareness. Approximately ninety percent of US adults consume below the Adequate Intake (AI) per NHANES analysis, and pregnancy-stage and lactation-stage adequacy is particularly concerning given the established neurodevelopmental importance. Choline serves four major biological functions: (1) acetylcholine biosynthesis, the foundational neurotransmitter for parasympathetic nervous system, muscle activation, and cognitive function, particularly memory consolidation and attention; (2) phosphatidylcholine biosynthesis, the most abundant phospholipid in cell membranes, accounting for approximately 40-50% of total phospholipid mass in mammalian cells, with critical roles in membrane structure, signaling, and lipid transport; (3) one-carbon metabolism, via choline oxidation to betaine (trimethylglycine), which donates methyl groups for homocysteine remethylation to methionine, integrating with folate and B12 pathways for DNA methylation, neurotransmitter synthesis, and detoxification; (4) lipid transport from liver, phosphatidylcholine is required for VLDL particle assembly and hepatic lipid export, making choline deficiency a direct cause of hepatic steatosis (fatty liver). The pregnancy and lactation evidence base is particularly substantial. Marie Caudill at Cornell's 2017 FASEB Journal trial randomized third-trimester pregnant women to 480mg/day (slightly above AI) versus 930mg/day choline supplementation; offspring assessed at age 7 showed sustained cognitive performance advantages in the higher-choline group, particularly in sustained attention tasks. This finding extends earlier work by Steven Zeisel at UNC characterizing choline's neurodevelopmental role through acetylcholine synthesis, membrane phospholipid provision for rapid neural growth, and methyl group provision for epigenetic programming. The pregnancy AI of 450mg/day (rising to 550mg/day during lactation) reflects substantially elevated requirements during these stages, yet only a tiny fraction of pregnant women consume even the AI through diet, and prenatal vitamins typically include minimal choline (~50mg). The egg yolk per-unit choline content (~147mg per large egg) makes eggs the single most practical dietary tool for closing the prenatal choline gap. The Polish "200 eggs during pregnancy" traditional dietary practice, which initially appeared as nutritional excess, actually approaches the Caudill 2017 evidence-based protocol when distributed across pregnancy. The TMAO cardiovascular controversy adds significant complexity to consumer choline supplementation. Trimethylamine N-oxide (TMAO) is a metabolite produced when gut microbiota convert dietary choline (and to a lesser extent L-carnitine) to trimethylamine (TMA), with subsequent hepatic oxidation to TMAO. Stanley Hazen's 2011 Nature paper from Cleveland Clinic demonstrated that elevated plasma TMAO correlated with cardiovascular events in observational cohorts, and that dietary choline loading in mice accelerated atherosclerosis. Subsequent research has produced a substantially more nuanced picture: TMAO elevation from choline supplementation is modest in most individuals and appears highly dependent on individual gut microbiome composition; the causal relationship between TMAO and cardiovascular events remains contested with substantial methodological debate; and the absolute risk attributable to choline-derived TMAO appears small compared to choline's established essentiality and demonstrated benefits. The current evidence position supports continued consumer choline supplementation at AI-level doses with awareness of the TMAO research as ongoing science rather than established cardiovascular contraindication.

Standard choline supplementation aims to meet the IOM Adequate Intake (AI), 425mg/day women, 550mg/day men, 450mg/day pregnancy, 550mg/day lactation. Given approximately 90% of US adults consume below AI per NHANES, supplementation at AI-bridging doses (200-500mg/day depending on dietary intake) is reasonable for most adults. The pregnancy evidence supports substantially higher dosing, Caudill 2017 trial used 930mg/day in third trimester for offspring cognitive benefit. The Upper Limit (UL) is 3500mg/day for adults (3000mg for adolescents, lower for younger children), reflecting fishy body odor at high doses (TMA accumulation in users with limited TMA-oxidation capacity) and mild GI effects. Take with or without food, absorption is acceptable either way; some users prefer with food to reduce mild GI sensitivity. For brain-targeted applications, alpha-GPC (300-1200mg/day) or CDP-choline / citicoline (250-1000mg/day) provide brain-penetrant forms with more direct cognitive effect potential than choline bitartrate alone. Forms matter substantially for clinical application: choline bitartrate is cost-effective for general AI support but less brain-penetrant; alpha-GPC and CDP-choline have superior blood-brain barrier penetration; phosphatidylcholine from lecithin provides comprehensive membrane phospholipid support. Egg yolks at ~147mg choline per large egg provide the most practical dietary tool, two eggs daily provides ~300mg dietary choline approaching AI for many adults. The pregnancy context particularly warrants explicit choline planning given the Caudill 2017 evidence and the fact that standard prenatal vitamins provide minimal choline (~50mg, far below the 450mg AI requirement). The TMAO controversy supports cardiology coordination for high-dose supplementation (>1g/day) in established cardiovascular disease; AI-level intake is universally supported.

AI women

425mg/day

AI men

550mg/day

AI pregnancy

450mg/day

AI lactation

550mg/day

Caudill 2017 pregnancy trial dose

930mg/day third trimester

Upper Limit (UL) adults

3500mg/day

Egg yolk choline content

~147mg per large egg

Beef liver choline content

~400mg per 100g serving

• Phosphatidylcholine (Lecithin)

  Rating: gold

  The dominant form of choline in dietary egg yolks, liver, and high-quality lecithin supplements. Sunflower lecithin (preferred over soy for users with soy sensitivity) and soy lecithin both provide phosphatidylcholine; commercial liquid lecithin or granular forms vary in PC concentration. Egg yolks are the most practical dietary source at ~147mg choline per large egg. Reasonable foundation for general choline status.

• Choline Bitartrate

  Rating: gold

  Most cost-effective concentrated choline supplement form (approximately 41% choline by weight). Used in many prenatal supplement formulations and general choline support products. Excellent for closing AI gap in users with low dietary choline intake. Less brain-penetrant than alpha-GPC or CDP-choline. Reasonable choice for general choline supplementation; not preferred for targeted cognitive enhancement.

• Alpha-GPC (L-Alpha-Glycerylphosphorylcholine)

  Rating: gold

  Brain-penetrant choline form (approximately 40% choline by weight) that crosses the blood-brain barrier efficiently. Used in nootropic protocols, age-related cognitive support, and Italian pharmaceutical use (Gliatilin) for vascular cognitive impairment. Premium pricing relative to choline bitartrate. Higher bioavailability for brain-targeted applications; reasonable for users prioritizing cognitive function.

• CDP-Choline (Citicoline)

  Rating: gold

  Cytidine diphosphate-choline, brain-penetrant nucleotide form that provides both choline and cytidine for phosphatidylcholine synthesis. Italian/Japanese pharmaceutical heritage (Cognizin branded form from Kyowa Hakko). Substantial clinical evidence in age-related cognitive decline (Nakazawa 2014), stroke recovery, vascular cognitive impairment. Premium pricing; mechanistically distinct from alpha-GPC despite both being brain-penetrant.

• Choline Chloride

  Rating: good

  Inorganic choline salt with high choline content. Common in feed/agricultural use; less common in consumer supplements due to hygroscopic handling challenges. Acceptable bioavailability when properly formulated. Less preferred than choline bitartrate for consumer use.

• Choline Citrate

  Rating: good

  Citrate salt with modest choline content (~30% by weight). Some consumer products use this form. Acceptable bioavailability; reasonable cost-effective alternative to choline bitartrate.

• Phosphatidylserine + Phosphatidylcholine Combinations

  Rating: good

  Comprehensive brain phospholipid formulations combining phosphatidylcholine with phosphatidylserine (PS). Mechanistically reasonable for brain phospholipid support; verify both PC and PS doses rather than relying on category positioning. Common in premium brain supplement formulations.

• Egg Yolk (Whole Food)

  Rating: gold

  The single most practical dietary source of bioavailable choline, approximately 147mg per large egg. Two eggs daily provides ~300mg dietary choline (approaching AI for many adults). Pregnancy-stage particular value given Caudill 2017 evidence. The "egg yolk during pregnancy" guidance is among the most actionable nutritional recommendations.

• Beef Liver / Organ Meats

  Rating: gold

  Highest natural choline content (approximately 400mg per 100g serving). Traditional preconception and pregnancy food in multiple cultures. Reasonable foundation for users including organ meats in diet. Desiccated liver capsules provide concentrated alternative for users not consuming fresh liver.

• Pregnancy (third trimester especially)

  Strength of evidence for this group: strong

  Caudill 2017 FASEB Journal trial supports 930mg/day choline (substantially above 450mg AI) during third trimester for sustained offspring cognitive advantages at age 7. The strongest pregnancy supplementation evidence in any non-folate nutrient. Coordinate with OB-GYN; consider prenatal choline supplementation explicitly rather than relying on standard prenatal vitamins (which provide minimal choline). Eggs provide practical dietary tool for closing the gap.

• Lactation

  Strength of evidence for this group: modest

  AI rises to 550mg/day during lactation reflecting substantial choline transfer to breastmilk. Maternal choline status affects breastmilk choline content; supplementation reasonable for users seeking optimal breastfeeding nutrition. Egg-rich diet plus targeted supplementation reasonable approach.

• NAFLD (non-alcoholic fatty liver disease)

  Strength of evidence for this group: modest

  Choline deficiency directly causes hepatic steatosis (Buchman 1995 foundational evidence). Reasonable component of comprehensive NAFLD management, though most NAFLD patients are not choline-deficient as primary etiology. Specialist hepatology coordination; not standalone NAFLD treatment.

• TPN (total parenteral nutrition)

  Strength of evidence for this group: strong

  Long-term TPN without choline supplementation produces hepatic steatosis (Buchman 1995). Choline is essentially universally added to modern TPN formulations. This is clinical pharmaceutical use case, not consumer supplementation, but establishes the unambiguous essentiality framework.

• Vegetarians / vegans

  Strength of evidence for this group: modest

  Plant-based diets typically substantially lower in choline than omnivorous diets (eggs, liver, meat being the richest sources). Vegans particularly likely to fall below AI; lacto-ovo vegetarians with regular egg consumption closer to AI. Reasonable targeted supplementation for vegan adults, particularly during pregnancy and lactation.

• Athletes (potential ergogenic)

  Strength of evidence for this group: cautious

  Endurance athletes show plasma choline reduction during prolonged exertion; some preliminary evidence for choline supplementation supporting endurance performance. Effect sizes preliminary and inconsistent; reasonable component of comprehensive sport nutrition but not primary ergogenic supplement.

• Age-related cognitive decline (CDP-choline / alpha-GPC)

  Strength of evidence for this group: modest

  Nakazawa 2014 systematic review of CDP-choline in age-related cognitive decline supports modest cognitive benefits. Alpha-GPC has similar Italian pharmaceutical inheritance (Gliatilin) in vascular cognitive impairment. Reasonable component of comprehensive cognitive support in older adults; not substitute for established cognitive impairment management.

• Stroke recovery (CDP-choline)

  Strength of evidence for this group: modest

  Substantial Italian/Japanese pharmaceutical use of CDP-choline (citicoline) in ischemic stroke recovery. Recent rigorous Western trials (ICTUS 2012, NEJM) showed less dramatic benefits than earlier studies suggested. Specialist neurology coordination; established use case in some healthcare systems.

• Bipolar depression adjunctive (CDP-choline preliminary)

  Strength of evidence for this group: cautious

  Preliminary evidence (Zhu 2020) for CDP-choline as adjunct in bipolar depression. Effect sizes modest; reasonable specialist consideration but not established treatment.

• Genetic variants affecting choline status (PEMT, MTHFD1)

  Strength of evidence for this group: modest

  Genetic polymorphisms in choline pathway genes (PEMT phosphatidylethanolamine N-methyltransferase, MTHFD1 methylenetetrahydrofolate dehydrogenase) substantially affect individual choline requirements. Users with these variants may benefit from higher dietary or supplemental choline. Genetic testing available but not routinely recommended; reasonable consideration for users with persistent choline-related symptoms.

• Cardiovascular disease (TMAO concern)

  Strength of evidence for this group: cautious

  The TMAO research (Wang 2011 and subsequent) creates theoretical caution about high-dose choline supplementation in established cardiovascular disease. Current evidence position: continued AI-level intake supported; high-dose supplementation in cardiovascular patients warrants cardiology coordination. Avoid recommending high-dose choline (>1g/day) in established CVD without specialist input.

• Memory and learning enhancement (healthy adults)

  Strength of evidence for this group: cautious

  Limited evidence for choline supplementation enhancing memory or learning in healthy non-deficient adults. Mechanistic plausibility through acetylcholine synthesis support; clinical effect-size evidence weak in healthy users. Reasonable component of comprehensive cognitive nutrition; not foundational nootropic.

• Folate (5-MTHF)

  Interaction: synergy

  Choline and folate share one-carbon metabolism pathways through betaine (from choline) donating methyl groups for homocysteine remethylation. Combined supplementation supports comprehensive methylation; particularly relevant in pregnancy where both nutrients support neural development.

• Vitamin B12

  Interaction: synergy

  B12 is cofactor in methionine synthase enzyme that uses 5-methylfolate (and betaine from choline) for homocysteine remethylation. Comprehensive methylation cofactor combination.

• Phosphatidylserine

  Interaction: synergy

  Common combination in comprehensive brain phospholipid support, phosphatidylcholine + phosphatidylserine together provide major membrane phospholipid substrate. Mechanistically integrated for cognitive applications.

• Omega-3 (EPA/DHA)

  Interaction: synergy

  DHA and phosphatidylcholine integrate as phosphatidylcholine-DHA in cell membranes and synaptic structures. Common combination in pregnancy nutrition given complementary neurodevelopmental contributions.

• Vitamin D3

  Interaction: synergy

  No direct mechanism interaction but common combination in comprehensive prenatal supplementation. Both have evidence for neurodevelopmental contributions.

• Methionine and Betaine

  Interaction: synergy

  Closely related one-carbon metabolism nutrients. Betaine (trimethylglycine, TMG) is choline's oxidation product and direct methyl donor; methionine is downstream methylation substrate. Comprehensive methylation supplementation context.

• L-Carnitine

  Interaction: caution

  L-carnitine is also gut-bacteria substrate for TMA → TMAO production (Koeth 2013). Combined high-dose supplementation may produce additive TMAO elevation. Cardiology coordination for users with established cardiovascular disease combining both.

• Cardiovascular Disease (TMAO Awareness)

  Interaction: caution

  High-dose choline supplementation (>1g/day) in established cardiovascular disease warrants cardiology coordination given TMAO research. AI-level intake is universally supported.

• Trimethylaminuria (TMAU)

  Interaction: avoid

  Genetic condition (FMO3 mutations) causing inability to oxidize TMA to TMAO, accumulating TMA produces fish-odor syndrome. Choline supplementation worsens symptoms. Genetic specialist coordination required for diagnosed TMAU.

• Acetylcholinesterase Inhibitors (Donepezil)

  Interaction: synergy

  Mechanistically complementary, choline provides acetylcholine substrate; acetylcholinesterase inhibitors prevent acetylcholine breakdown. Common combination consideration in age-related cognitive support; specialist neurology coordination for established AD treatment.

Look for: specific choline form disclosed (bitartrate, alpha-GPC, CDP-choline, phosphatidylcholine); elemental choline content per serving; appropriate form for intended use (bitartrate for general AI support, alpha-GPC or CDP-choline for brain-targeted applications); Cognizin branding for premium CDP-choline; sunflower lecithin specification for users avoiding soy; USP or NSF third-party verification; reputable manufacturer with quality control disclosure. Avoid: products without specific choline form disclosure; proprietary "nootropic" blends obscuring choline dose; very low-dose products inadequate for AI support; products from manufacturers without third-party testing disclosure; pharmaceutical CDP-choline marketed outside prescription channels.

Choline's discovery came in 1862 through Adolph Strecker, a German chemist who isolated and named the compound from bile (Greek chole, "bile"). The basic chemistry of choline was characterized through subsequent 19th-century German organic chemistry. The biological significance emerged slowly through the early 20th century, Otto Loewi's 1921 demonstration of "vagusstoff" (later identified as acetylcholine) established the neurotransmitter role indirectly. Charles Best (Toronto, co-discoverer of insulin) and colleagues demonstrated in 1932 that lecithin and choline prevented fatty liver in pancreatectomized dogs, foundational evidence linking choline to hepatic lipid metabolism. The modern essentiality research era developed substantially through Steven Zeisel's decades-long work at UNC Chapel Hill (1980s-2010s). Zeisel's group characterized choline depletion-repletion methodology in human subjects, demonstrated muscle and liver dysfunction with deficiency, characterized genetic variation in choline requirements (PEMT, MTHFD1, CHDH polymorphisms), and provided the scientific foundation for IOM 1998 establishment of choline as essential nutrient with Adequate Intake values. The TPN (total parenteral nutrition) clinical inheritance provided the unambiguous interventional evidence. Alan Buchman's 1995 Hepatology paper demonstrated that adult patients on long-term TPN without choline developed hepatic steatosis, and that choline addition reversed the steatosis. This established choline as essential nutrient with measurable clinical consequences in adult human populations, foundational evidence for the broader essentiality framework. The IOM 1998 Adequate Intake establishment represents the most recent essential nutrient designation by IOM. Choline AIs were established: 425mg/day women, 550mg/day men, 450mg/day pregnancy, 550mg/day lactation. The Upper Limit (UL) was set at 3500mg/day for adults based on fishy body odor at high doses. The Caudill prenatal cognitive trial era emerged in 2017 with the Cornell-based FASEB Journal publication. Marie Caudill's randomized trial of 480mg/day versus 930mg/day choline during third trimester produced offspring cognitive performance advantages at age 7, particularly in sustained attention tasks. This was among the most rigorous prenatal nutrition trials of the 2010s and substantially elevated awareness of the prenatal choline gap. The TMAO cardiovascular controversy emerged from Stanley Hazen's 2011 Nature paper at Cleveland Clinic. The TMAO-cardiovascular connection generated substantial concern about choline supplementation in cardiovascular contexts. Subsequent research has produced more nuanced picture: TMAO elevation from typical choline supplementation is modest in most individuals, dependent on individual gut microbiome composition; the causal relationship between TMAO and cardiovascular events remains debated with substantial methodological disagreement; the absolute risk attributable to choline-derived TMAO appears modest compared to choline's established essentiality and benefits. The Wallace 2018 NHANES analysis demonstrating ~90% of US adults consuming below choline AI established the population-level inadequacy concern. Subsequent integrative medicine and functional nutrition advocacy has emphasized the choline gap as significant public health concern, particularly during pregnancy and lactation. The modern consumer market has matured substantially through the 2010s-2020s with prenatal-specific choline supplements (Needed, Theralogix, FullWell, and others) explicitly designed to address the prenatal choline gap. The American Medical Association in 2017 acknowledged the need for prenatal vitamin choline content; many but not all prenatal vitamins have updated formulations accordingly. The "egg yolk during pregnancy" guidance has emerged as among the most actionable nutritional recommendations of recent decades.

1. 1862Strecker (Germany) isolates and names choline from bile
2. 1921Loewi demonstrates "vagusstoff" (later identified as acetylcholine)
3. 1932Best and Hershey demonstrate choline prevents fatty liver in pancreatectomized dogs
4. 1957Schwarz vitamin E-selenium hepatic necrosis (choline-selenium interaction)
5. 1980s-2010sZeisel decades of essentiality characterization at UNC
6. 1995Buchman TPN hepatic steatosis (Hepatology)
7. 1998IOM establishes choline as essential nutrient with AI values
8. 2006Da Costa human depletion characterization
9. 2011Wang/Hazen TMAO cardiovascular framework (Nature, Cleveland Clinic)
10. 2017Caudill prenatal cognitive trial (FASEB Journal, Cornell)
11. 2018Wallace NHANES ~90% below AI documentation
12. 2017AMA acknowledges need for prenatal vitamin choline content
13. 2010s-2020sPrenatal-specific choline supplement category emergence

• Whether the Caudill 2017 prenatal choline trial findings will translate into broader clinical practice changes, current prenatal vitamins typically provide minimal choline despite the evidence base.
• Whether the TMAO cardiovascular research will mature into actionable clinical guidance, current evidence position supports continued AI-level intake but high-dose supplementation in CVD warrants cardiology input.
• Whether genetic testing for choline pathway variants (PEMT, MTHFD1) should be routine in clinical nutrition assessment, currently available but not widely integrated.
• Whether the differential brain penetration of alpha-GPC vs CDP-choline produces clinically distinguishable cognitive outcomes in head-to-head trials.
• Whether choline has specific applications in liver disease beyond TPN-related steatosis and modest NAFLD evidence, broader hepatology applications remain preliminary.
• Whether the 90% below-AI population statistic represents widespread mild deficiency with subclinical consequences or normal range that does not require universal correction.
• Whether maternal choline status during preconception (rather than just pregnancy) affects offspring outcomes, current evidence focuses on pregnancy supplementation.
• How best to integrate choline guidance with established dietary recommendations, egg yolks face cardiovascular reputation challenges despite providing the most practical choline source.

Widely available globally as dietary supplement, food ingredient (lecithin), and pharmaceutical (CDP-choline in Italy and Japan). Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Major retail supplement brands include NOW Foods, Thorne, Pure Encapsulations, Designs for Health, Source Naturals (choline bitartrate), Jarrow Formulas (alpha-GPC), Life Extension (CDP-choline Cognizin), and many prenatal-focused brands. Cognizin (Kyowa Hakko Bio Japanese pharmaceutical-grade CDP-choline) carries premium pricing reflecting clinical inheritance and licensed branding. Egg yolks are universally available; beef liver and other organ meats available in most markets. Sunflower lecithin (preferred over soy for some users) is widely available. Pharmaceutical CDP-choline (Somazina, Ceraxon) is available by prescription in Italy, Japan, and select European markets for cognitive impairment indications. The choline category has matured substantially through the 2010s with prenatal-specific products from Needed, Theralogix, and similar brands explicitly designed to address the prenatal choline gap. Production is industrial-scale for choline bitartrate (commodity chemistry); alpha-GPC and CDP-choline involve more specialized pharmaceutical manufacturing.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Class

Essential nutrient (IOM 1998)

Discovery

1862 (Strecker, Germany; from bile)

IOM essentiality establishment

1998

AI women

425mg/day

AI men

550mg/day

AI pregnancy

450mg/day

What follows is unfinished work on our side, not a finding about Choline. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.